Evidence map›Paper›PMID 36863843›Full record

ArticleCold Spring Harbor molecular case studies2023

Ottavia Amato, Laurence Buisseret, Géraldine Gebhart, Nicolas Plouznikoff, Denis Larsimont, Ahmad Awada, Martine Piccart, Philippe Aftimos

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cold Spring Harbor molecular case studies, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Flavonoids extract fromWorld journal of experimental medicine · 2025
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 3 countries.

Ottavia AmatoOncology Medicine Department, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, 1070, Belgium.ORCID 0000-0002-3690-8542
Laurence BuisseretOncology Medicine Department, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, 1070, Belgium.
Géraldine GebhartNuclear Medicine Department, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, 1070, Belgium.
Nicolas PlouznikoffDepartment of Nuclear Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec H2X 354, Canada.
Denis LarsimontPathology Department, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, 1070, Belgium.
Ahmad AwadaOncology Medicine Department, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, 1070, Belgium.
Martine PiccartOncology Medicine Department, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, 1070, Belgium.
Philippe AftimosClinical Trials Conduct Unit, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, 1070, Belgium philippe.aftimos@bordet.be.
Université Libre de Bruxelles · BECentre Hospitalier de l’Université de Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As wider insights are gained on the molecular landscape of triple-negative breast cancer (TNBC), novel targeted therapeutic strategies might become an option in this setting as well. Activating mutations of

Indexed as

Proto-Oncogene Proteins c-aktTriple Negative Breast NeoplasmsClass I Phosphatidylinositol 3-KinasesHumansPhosphatidylinositol 3-KinasesSignal TransductionTOR Serine-Threonine KinasesClass I Phosphatidylinositol 3-KinasesMTOR protein, humanPhosphatidylinositol 3-KinasesPIK3CA protein, humanProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinasesneoplasm of the breast

Identifiers

PMID36863843
PMCPMC10240844
OpenAlexW4323035939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.